Reports Q3 revenue $1B, consensus $990.79M. James C. Foster, Chair, President and Chief Executive Officer, said, “Our solid third-quarter financial results demonstrate that the demand for our extensive portfolio of early-stage research and manufacturing products and services remains stable. We believe that positive signals are beginning to emerge which indicate that the industry may be on a path towards recovery; however, sustained improvement in our business will take time. There is still some uncertainty in the healthcare sector, so we are remaining cautious at this time.”
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River Laboratories Intl (CRL) Q3 Earnings Cheat Sheet
- Charles River enters ADC drug discovery pact with Francis Crick Institute
- Charles River enters strategic collaboration with X-Chem
- Charles River price target raised to $174 from $155 at Mizuho
- Strategic Divestiture and Value Unlocking: Charles River Labs’ Path to Growth
